No Data
Chengdu Easton Biopharmaceuticals (688513.SH): repurchased shares through centralized bidding trade, reaching 2% of the total share capital.
Gelonghui January 1st丨Chengdu Easton Biopharmaceuticals (688513.SH) announced that in December 2024, the company repurchased 0.2222 million shares through centralized bidding, accounting for 0.1259% of the company's current total share capital, with a maximum purchase price of 30.99 yuan/share and a minimum price of 29.85 yuan/share. The total transaction amount was 6.7647 million yuan (excluding stamp duty, transaction commissions, and other trading fees). As of the end of December 2024, the company has cumulatively repurchased 3.539 million shares through centralized bidding, accounting for the company's current total share capital.
The Recent Pullback Must Have Dismayed Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Insiders Who Own 49% of the Company
Chengdu Easton Biopharmaceuticals (688513.SH): Participating in the national pharmaceutical centralized procurement and expected to be selected.
On December 13, Glorious Exchange reported that Chengdu Easton Biopharmaceuticals (688513.SH) announced its participation in the bidding work organized by the National Joint Procurement Office for the tenth batch of national centralized pharmaceutical procurement. According to the announcement published on December 12, 2024, on the Shanghai Sunlight Medical Procurement Network, the company’s Sodium Gluconate Injection and Nicorandil Injection are proposed to be awarded in this centralized procurement.
Chengdu Easton Biopharmaceuticals (688513.SH): The company did not implement share repurchases in November.
Gelonghui reported on December 2 that chengdu easton biopharmaceuticals (688513.SH) announced that in November 2024, the company did not implement share repurchases. As of the end of November 2024, the company has cumulatively repurchased 3,316,769 shares through centralized bidding, accounting for 1.8788% of the company’s current total share capital, with a highest purchase price of 56.05 yuan/share, a lowest price of 28.12 yuan/share, and a total transaction amount of 123,694,177.73 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Chengdu Easton Biopharmaceuticals Obtain Drug Registration for Ruxolitinib Phosphate Tablets
Chengdu Easton Biopharmaceuticals (688513.SH): The phosphate lebrutinib tablets have obtained a pharmaceutical registration certificate.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received approval from the National Medical Products Administration for the issuance of...
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E Ratio
No Data
